Virtual Reality for SCD VOC
NCT: NCT07674277 · NOT_YET_RECRUITING
Brief Summary
This pilot study will evaluate the feasibility, tolerability, and preliminary analgesic effect of headset-based virtual reality interventions for adults with sickle cell disease experiencing vaso-occlusive crisis treated in an infusion center. Participants will be enrolled during routine outpatient sickle cell clinic visits and may receive study interventions during future qualifying infusion center visits for vaso-occlusive pain. Using a randomized, two-period crossover design, each participant will be assigned to receive two of three headset-based conditions across separate visits: sham 2D headset control, passive immersive 3D virtual reality, or active immersive interactive 3D virtual reality. The primary outcome is pain burden during the first 60 minutes after intervention start, measured as area under the curve of 0-10 numeric rating scale pain scores. Secondary outcomes include feasibility of intervention delivery, headset tolerability, pain at 120 minutes, opioid use, and participant-reported immersion and acceptability.
Frequently Asked Questions
What is Virtual Reality for SCD VOC?
Virtual Reality for SCD VOC is a clinical trial registered under NCT07674277. Current status: NOT_YET_RECRUITING.
What is the status of NCT07674277?
The current status of NCT07674277 (Virtual Reality for SCD VOC) is: NOT_YET_RECRUITING.
When did Virtual Reality for SCD VOC start?
Virtual Reality for SCD VOC started on 2026-08-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.